Home › News › Market

Innovent Biologics Secures NRDL Inclusion for Seven Innovative Medicines in China

Innovent Biologics Secures NRDL Inclusion for Seven Innovative Medicines in China

Innovent Biologics has announced that seven of its innovative medicines have been included in China's updated National Reimbursement Drug List (NRDL) 2026, expanding reimbursement coverage across oncology, cardiovascular, metabolic and autoimmune diseases. The revised list will come into effect on January 1, 2027.

The newly included products are mazdutide, Pecondle (picankibart injection), Tabosun (ipilimumab N01 injection) and Vanflyta (quizartinib). Additionally, two new indications for TYVYT (sintilimab injection) and Jaypirca (pirtobrutinib) have been added, while Sintbilo (tafolecimab injection) has secured successful reimbursement renewal.

The newly covered indications include treatments for type 2 diabetes, moderate to severe plaque psoriasis, colon cancer, Acute Myeloid Leukaemia (AML), renal cell carcinoma and Chronic Lymphocytic Leukaemia (CLL). The expanded coverage is expected to improve patient access to innovative therapies and reduce treatment-related financial burdens.

Commenting on the development, Dr Michael Yu, Founder, Chairman and CEO of Innovent, said the inclusion of seven medicines would strengthen the company's contribution to improving access to innovative treatments. He added that Innovent's NRDL-covered portfolio had expanded to 17 medicines, cumulatively benefiting more than 20 million patients.

Among the newly included medicines, mazdutide, a dual GCG/GLP-1 receptor agonist, has been added for adults with type 2 diabetes, while picankibart, an IL-23p19 inhibitor, has been included for adults with moderate to severe plaque psoriasis. Ipilimumab N01, a CTLA-4 inhibitor, has been included in combination with sintilimab for the neoadjuvant treatment of certain patients with resectable colon cancer.

Quizartinib, a type II FLT3 inhibitor, has also secured NRDL inclusion for newly diagnosed FLT3-ITD-positive AML. Meanwhile, new indications for sintilimab and pirtobrutinib expand reimbursement coverage for certain patients with renal cell carcinoma and CLL, respectively. Tafolecimab, a fully human PCSK9 monoclonal antibody, has successfully renewed its reimbursement coverage.

The updated NRDL inclusion marks an expansion of Innovent's commercial portfolio in China and supports the company's efforts to improve the affordability and accessibility of innovative medicines across major disease areas.

More news about: market | Published by News Bureau | November - 16 - 2026

Last news about this category


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members